Artiva Biotherapeutics, Inc.

ARTV

Healthcare Biotechnology

Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023.

EPS
+27.6%
Free cash flow
+13.6%

Quarter to June 2026, against a year earlier

4.15 0.02 +0.48%
Market cap
$202.9M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.2×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
352.28 88.74 112.67 129.52
Total non-current assets
16.36 17.22 18.27 19.34
Total Assets
368.63 105.96 130.94 148.86
Total current liabilities
14.58 10.88 13.09 11.12
Total non-current liabilities
6.55 7.23 7.88 8.52
Total liabilities
21.13 18.11 20.97 19.64
Common Equity (Total)
347.50 87.85 109.97 129.22
Shareholders Equity (Total)
347.50 87.85 109.97 129.22

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026